文献速递主动脉疾病

中国大陆B型主动脉夹层胸主动脉腔内修复术后结局评估

The Evaluation of Outcomes after Thoracic Endovascular Aortic Repair for Type B Aortic Dissection in Mainland China.
PubMed 文献 · Ann Vasc Surg · 2024-03-18

该系统评价与Meta分析检索1999年1月至2023年10月PubMed、Cochrane Library和Embase数据库,纳入25篇文献共3080例患者,评估中国大陆B型主动脉夹层行胸主动脉腔内修复术(TEVAR)后的死亡与结局,并与西方国家数据比较。合并院内死亡率为2.2%(95%CI 1.6%-2.9%),中期(<5年)死亡率为5.1%(3.6%-7.3%)。与西方国家相比,中国大陆患者死亡率更低;作者结论认为中国大陆TEVAR结局与西方国家相当,大量患者接受TEVAR且表现良好支持在非复杂性TBAD中使用TEVAR。

要点

  • 纳入25篇文献共3080例患者,合并院内死亡率为2.2%(95%CI 1.6%-2.9%)。
  • 中期(<5年)死亡率为5.1%(95%CI 3.6%-7.3%),二次干预率为4.9%(95%CI 4.0%-6.0%)。
  • 非复杂性TBAD亚组院内死亡率为0.5%(95%CI 0.2%-1.5%),中期死亡率为0.6%(95%CI 0.2%-1.7%)。

核心结论

  • 在中国大陆,B型主动脉夹层腔内治疗结局与西方国家相当。
  • 中国大陆接受TEVAR的患者数量大且表现良好,支持在非复杂性TBAD中使用TEVAR。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA声明,检索1999年1月至2023年10月PubMed、Cochrane Library和Embase数据库。
  • 纳入25篇文献,共3080例患者。
  • 主要结局为院内死亡率和中期(<5年)死亡率。

主要发现

  • 合并院内死亡率为2.2%(95%CI 1.6%-2.9%)。
  • 主要围术期并发症包括卒中2.4%(95%CI 1.8%-3.3%)、脊髓缺血1.4%(95%CI 1.0%-2.2%)、逆行性A型主动脉夹层1.2%(95%CI 0.8%-1.8%)、I型内漏5.6%(95%CI 3.6%-8.6%)、内脏缺血1.0%(95%CI 0.5%-2.1%)和急性肾衰竭2.8%(95%CI 2.0%-3.8%)。
  • 中期死亡率为5.1%(95%CI 3.6%-7.3%),二次干预率为4.9%(95%CI 4.0%-6.0%),转为开放手术率为1.7%(95%CI 1.0%-2.9%)。
  • 非复杂性TBAD亚组院内死亡率为0.5%(95%CI 0.2%-1.5%),中期死亡率为0.6%(95%CI 0.2%-1.7%)。
  • 与西方国家数据比较,中国大陆患者死亡率更低。

临床怎么用

  • 作者结论认为中国大陆TEVAR结局与西方国家相当,大量患者接受TEVAR且表现良好支持在非复杂性TBAD中使用TEVAR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To assess the mortality and outcomes after thoracic endovascular aortic repair (TEVAR) in patients with type B aortic dissection (TBAD) in mainland China, and to compare these outcomes with data from Western countries, while analyzing the potential reasons for differences among different countries. METHODS: An extensive literature search spanning from January 1999 to October 2023 was conducted using PubMed, Cochrane Library, and Embase databases for studies on endovascular treatment for TBAD. This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Data extraction and analysis followed the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Primary outcomes were in-hospital mortality and mid-term (< 5 years) mortality. RESULTS: Based on 25 publications (3,080 patients), pooled estimate for in-hospital mortality was 2.2% (95% confidence interval, 1.6%-2.9%). Major perioperative complications included stroke (2.4% [1.8%-3.3%]), spinal cord ischemia (1.4% [1.0%-2.2%]), retrograde type A aortic dissection (1.2% [0.8%-1.8%]), type I endoleak (5.6% [3.6%-8.6%]), visceral ischemia (1.0% [0.5%-2.1%]), and acute renal failure (2.8% [2.0%-3.8%]). Mid-term mortality was 5.1% (3.6%-7.3%), and secondary intervention rate was 4.9% (4.0%-6.0%) with 1.7% (1.0%-2.9%) conversion rate to open surgery. In subgroup analysis based on uncomplicated TBAD, in-hospital and mid-term mortality was 0.5% (0.2%-1.5%) and 0.6% (0.2-1.7%), respectively. Compared with data from Western countries, mainland Chinese patients had a lower mortality. CONCLUSIONS: In mainland China, the outcomes of endovascular treatment for TBAD are comparable to those of Western countries. The large number of patients undergoing TEVAR in mainland China and its good performance support the use of TEVAR in uncomplicated TBAD.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Jia H, Yuan P, Wu S, et al. The Evaluation of Outcomes after Thoracic Endovascular Aortic Repair for Type B Aortic Dissection in Mainland China. Ann Vasc Surg. 2024. PMID: 38508445. doi:10.1016/j.avsg.2023.12.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。